Healthy male or female participants, 18 to 60 years of age, inclusive.
Body mass index (BMI) between 18.0 and 32.0 kg/m\^²(kilograms per meter square.), inclusive.
In good health as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory evaluations.
Female participants must not be pregnant or breastfeeding.
Participants of reproductive potential must agree to follow protocol-specified contraception requirements.
You may not be if
Clinically significant medical condition or disease that may pose a safety risk or interfere with study participation or interpretation of study results.
Clinically significant cardiovascular disease or ECG abnormality, including clinically significant arrhythmia or prolonged QTcF(QT Interval Corrected for Heart Rate Using Fridericia's Formula).
Significant gastrointestinal disease, gastrointestinal surgery that could affect drug absorption, malabsorption syndrome, or inability to swallow oral medication.
History of suicidal ideation, suicide attempt, or major psychiatric illness within 6 months before informed consent.
Malignancy within the previous 5 years, except for protocol-specified nonmelanoma skin cancers or cervical carcinoma in situ.
Known hypersensitivity, intolerance, or allergy to apremilast.
Clinically significant renal or hepatic impairment, including estimated glomerular filtration rate (eGFR) \<70 mL/min/1.73 m\^²(millilitres per minute per 1.73 square meters) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>1.5 × the upper limit of normal.
Positive testing for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, except for protocol-specified hepatitis B results consistent with prior vaccination or prior infection.
Use of prohibited prescription or over-the-counter medications, herbal medicines, vitamins, or supplements within the protocol-specified period before study entry.
Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, before check-in.
Previous participation in this study or another study investigating apremilast, or previous receipt of apremilast.
History of alcohol or drug abuse within the protocol-specified periods, or positive alcohol or illicit drug testing.
Use of tobacco- or nicotine-containing products within 3 months before check-in.
Recent blood, plasma, or platelet donation outside the protocol-specified limits.
Poor peripheral venous access.
Unable or unwilling to comply with protocol-required dietary, lifestyle, or other study restrictions.
